Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The goal of this early phase, open-label, single arm clinical trial is to determine the 6-month effects and tolerability of NPC1 (parthenolide and ipriflavone) on biomarkers of Alzheimer's Disease among adults with objective indicators of seeding AD pathology that also have subjective cognitive concerns, Mild Cognitive Impairment, or Alzheimer's Disease (AD)